Autres langues Mainstay Medical International Irish S.E.

Actions

MSTY1

IE00BJYS1G50

Temps Différé Irish S.E. Autres places de cotation			Varia. 5j.	Varia. 1 janv.
- ^EUR	-.--%		+6,44 %	-38,57 %

12/03	Mainstay Medical Holdings plc annonce la publication de résultats cliniques comparant des patients plus âgés et des patients plus jeunes	CI
12/02	Mainstay Medical annonce avoir reçu l'approbation de la FDA pour l'étiquetage IRM du système de neurostimulation restauratrice Reactiv8®tm	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Mainstay Medical Holdings plc Announces Publication of Clinical Results Comparing Older Patients and Younger Patients	12/03
Mainstay Medical Holdings plc announced that it has received ?115 million in funding from a group of investors	26/02
Mainstay Medical Holdings plc announced that it expects to receive funding	23/02
Mainstay Medical Announces Receipt of FDA Approval for MRI Labeling on Reactiv8® Restorative Neurostimulation Systemtm	12/02
Mainstay Medical Announces Completion of Enrollment of RESTORE Clinical Trial of ReActiv8® in the United States	29/08/23
Mainstay Medical Holdings plc Announces Publication of Three-Year Clinical Trial Data from Post-Market Clinical Follow-Up Registry of Reactiv8 in the United Kingdom	20/07/23
Mainstay Medical Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2022	28/03/23
Mainstay Medical Holdings plc Announces the Publication of Effect of Restorative Neurostimulation on Major Drivers of Chronic Low Back Pain Economic Impact	02/03/23
Mainstay Medical Announces Publication of Post-Market Clinical Trial Data from Ongoing ReActiv8®-C Study in Chronic Low Back Pain Patients	22/11/22
Mainstay Medical Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2021	28/03/22
Mainstay Medical Holdings plc Announces Publication of Two-Year Patient Outcomes Data from Reactiv8-B Clinical Trial Demonstrating Long-Term Efficacy of Reactiv8 Restorative Neurostimulation	06/01/22
Mainstay Medical Holdings plc Announces Appointment of Jeffrey Dunn and Eric Major to Its Board of Directors	14/12/21
Mainstay Medical Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2020	09/07/21
Mainstay Medical Announces Limited Announces Commercial Launch of ReActiv8® in US	29/06/21
Oxford Finance LLC Announces Closing of $50 Million Senior Secured Term Loan with Mainstay Medical Holdings plc	20/04/21
Mainstay Medical Announces Commercial Launch of ReActiv8® in Australia	08/03/21
Mainstay Medical Holdings plc announced that it has received $108 million in funding from Ally Bridge Group, KCK Group, Sofinnova Partners SAS, Fountain Healthcare Partners, and another investor	16/02/21
Mainstay Medical Holdings plc announced a financing transaction	09/02/21
Mainstay Medical Holdings plc Announces U.S. FDA Approval of ReActiv8® Neurostimulation System for Chronic Low Back Pain	22/06/20
Mainstay Medical : announces Scheme becoming effective	05/06/20

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Mainstay Medical International Irish S.E.

Actions

MSTY1

IE00BJYS1G50

Autres langues

Filtres